Cooling down inflammation in type 2 diabetes: how strong is the evidence for cardiometabolic benefit?
- 740 Downloads
Chronic inflammation is supposed to be an important mediator of cardiometabolic dysfunctions seen in type 2 diabetes. In this mini-review, we collected evidence (PubMed) from randomized controlled trials (through March 2016) evaluating the effect of anti-inflammatory drugs on indices of glycemic control and/or cardiovascular events in people with type 2 diabetes. Within the last 25 years, many anti-inflammatory drugs have been tested in type 2 diabetes, including hydroxychloroquine, anti-tumor necrosis factor therapies (etanercept and infliximab), salsalate, interleukin-1 antagonists (anakinra, canakinumab, gevokizumab, LY2189102), and CC-R2 antagonists. Despite being promising, the observed effects on HbA1c or glucose control remain rather modest in most clinical trials, especially with the new drugs. There are many trials underway with anti-inflammatory agents to see whether patients with cardiovascular diseases and/or type 2 diabetes may have clinical benefit from marked reductions in circulating inflammatory markers. Until now, a large trial with losmapimod (a p38 inhibitor) among patients with acute myocardial infarction, including one/third of diabetic patients, showed no reduction in the risk of major ischemic cardiovascular events. Further evidence is warranted in support of the concept that targeting inflammation pathways may ameliorate glycemic control and also reduce cardiovascular complications in type 2 diabetes.
KeywordsInflammation Type 2 diabetes Anti-inflammatory drugs Glycemic control Cardiovascular complications
Compliance with ethical standards
Conflict of Interest
D. G. and K. E. received speaker fees from Lilly, SANOFI, and NOVARTIS.
- 6.Y.C Kaplan, J. Ozsarfati, C. Nickel, G. Koren, Reproductive outcomes following hydroxychloroquine use for autoimmune diseases: a systematic review and meta-analysis. Br. J. Clin. Pharmacol. (2015 Dec 23). doi: 10.1111/bcp.12872. [Epub ahead of print]
- 11.T.S. Sharma, M.C. Wasko, X. Tang, D. Vedamurthy, X. Yan, J. Cote, A. Bili, Hydroxychloroquine use is associated with decreased incident cardiovascular events in rheumatoid arthritis patients. J. Am. Heart. Assoc. 4, 5 (2016)Google Scholar
- 19.J. Zhang, F. Xie, H. Yun, et al, Comparative effects of biologics on cardiovascular risk among older patients with rheumatoid arthritis. Ann. Rheum. Dis. (2016 Jan 20). doi: 10.1136/annrheumdis-2015-207870. [Epub ahead of print]
- 23.A.B. Goldfine, V. Fonseca, K.A. Jablonski, L. Pyle, M.A. Staten, S.E. Shoelson, TINSAL-T2D (TargetingInflammation Using Salsalate in Type 2 Diabetes) Study Team. The effects of salsalate on glycemic control in patients with type 2 diabetes: a randomized trial. Ann. Intern. Med. 152, 346–357 (2010)CrossRefPubMedPubMedCentralGoogle Scholar
- 24.A.B. Goldfine, V. Fonseca, K.A. Jablonski, Y.D. Chen, L. Tipton, M.A. Staten, S.E. Shoelson, Targeting inflammation using salsalate in type 2 diabetes study team. Salicylate (salsalate) in patients with type 2 diabetes: a randomized trial. Ann. Intern. Med. 159, 1–12 (2013)CrossRefPubMedPubMedCentralGoogle Scholar
- 30.P.M. Ridker, C.P. Howard, V. Walter, on behalf of the CANTOS Pilot Investigative Group et al., Effects of interleukin-1β inhibition with canakinumab on hemoglobin A1c, lipids, C-reactive protein, interleukin-6, and fibrinogen. A phase IIb randomized, placebo-controlled trial. Circulation 126, 2739–2748 (2012)CrossRefPubMedGoogle Scholar
- 31.C. Cavelti-Weder, A. Babians-Brunner, C. Keller, M.A. Stahel, M. Kurz-Levin, H. Zayed, A.M. Solinger, T. Mandrup-Poulsen, C.A. Dinarello, M.Y. Donath, Effects of gevokizumab on glycemia and inflammatory markers in type 2 diabetes. Diabetes Care 35, 1654–1662 (2012)CrossRefPubMedPubMedCentralGoogle Scholar
- 32.J. Sloan-Lancaster, E. Abu-Raddad, J. Polzer, J.W. Miller, J.C. Scherer, A. De Gaetano, J.K. Berg, W.H. Landschulz, Double-blind, randomized study evaluating the glycemic and anti-inflammatory effects of subcutaneous LY2189102, a neutralizing IL-1β antibody, in patients with type 2 diabetes. Diabetes Care 36, 2239–2246 (2013)CrossRefPubMedPubMedCentralGoogle Scholar